FDA approval requires a complete review of benefits, risks, dosing, safety data, manufacturing quality, and patient use instructions
Step 5: Label the vial with the date of reconstitution, the concentration (e.g., "10mg in 3mL = 3.33mg/mL"), and the 28-day expiration date
[UPDATED MONTHLY: MOAA's TRICARE Toolkit] For both Wegovy and Zepbound, TRICARE prior authorization requires adult patients to: Have a BMI greater than or equal to 30 or a BMI greater than or equal to 27 with additional risk factors (e.g., hypertension, sleep apnea)
Temporary nausea, semaglutide fatigue , or headache can occur as your body adjusts to a higher dose
Protect the vial from excessive light to preserve the medication
severe rash Symptoms of severe dehydration from persistent vomiting or diarrhea Sudden severe upper right abdominal pain, fever, or yellowing of the skin (possible gallbladder disease) Use in Pregnancy and Breastfeeding Semaglutide may cause fetal harm